SCYX vs. MRNS, IFRX, TPST, HOOK, JAGX, MNOV, RLYB, DERM, ASMB, and VTVT
Should you be buying SCYNEXIS stock or one of its competitors? The main competitors of SCYNEXIS include Marinus Pharmaceuticals (MRNS), InflaRx (IFRX), Tempest Therapeutics (TPST), Hookipa Pharma (HOOK), Jaguar Health (JAGX), MediciNova (MNOV), Rallybio (RLYB), Journey Medical (DERM), Assembly Biosciences (ASMB), and vTv Therapeutics (VTVT). These companies are all part of the "pharmaceutical preparations" industry.
Marinus Pharmaceuticals (NASDAQ:MRNS) and SCYNEXIS (NASDAQ:SCYX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, community ranking, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.
Marinus Pharmaceuticals has a beta of 1.14, meaning that its share price is 14% more volatile than the S&P 500. Comparatively, SCYNEXIS has a beta of 1.49, meaning that its share price is 49% more volatile than the S&P 500.
SCYNEXIS has a net margin of 72.18% compared to SCYNEXIS's net margin of -513.80%. Marinus Pharmaceuticals' return on equity of 112.89% beat SCYNEXIS's return on equity.
Marinus Pharmaceuticals currently has a consensus target price of $13.79, indicating a potential upside of 936.52%. SCYNEXIS has a consensus target price of $15.00, indicating a potential upside of 441.52%. Given SCYNEXIS's higher possible upside, equities research analysts plainly believe Marinus Pharmaceuticals is more favorable than SCYNEXIS.
SCYNEXIS has higher revenue and earnings than Marinus Pharmaceuticals. Marinus Pharmaceuticals is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks.
98.8% of Marinus Pharmaceuticals shares are owned by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are owned by institutional investors. 5.5% of Marinus Pharmaceuticals shares are owned by insiders. Comparatively, 4.4% of SCYNEXIS shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
In the previous week, Marinus Pharmaceuticals had 7 more articles in the media than SCYNEXIS. MarketBeat recorded 13 mentions for Marinus Pharmaceuticals and 6 mentions for SCYNEXIS. Marinus Pharmaceuticals' average media sentiment score of 0.97 beat SCYNEXIS's score of -0.01 indicating that SCYNEXIS is being referred to more favorably in the news media.
SCYNEXIS received 79 more outperform votes than Marinus Pharmaceuticals when rated by MarketBeat users. Likewise, 70.24% of users gave SCYNEXIS an outperform vote while only 69.27% of users gave Marinus Pharmaceuticals an outperform vote.
Summary
SCYNEXIS beats Marinus Pharmaceuticals on 12 of the 18 factors compared between the two stocks.
Get SCYNEXIS News Delivered to You Automatically
Sign up to receive the latest news and ratings for SCYX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SCYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SCYNEXIS Competitors List
Related Companies and Tools
